Last Updated on February 27, 2023


Moderna made a $400 million license agreement payment to Dr. Anthony Fauci’s former government organization the National Institute of Allergy and Infectious Diseases (NIAID), proving the crony relationship between Big Pharma and Big Government during the age of the Coronavirus scamdemic. NATIONAL FILE previously reported that National Institutes of Health, of which NIAID is a member, actually has an intellectual property ownership stake in the Moderna Coronavirus injection.

Moderna kicked $400 million to NIAID, as revealed in a company earnings release. Moderna refers to the payment as a “catch-up payment.” Dr. Anthony Fauci headed NIAID for decades, including during the start of the Coronavirus scamdemic, before recently stepping away from the role. As NATIONAL FILE first reported, Fauci’s NIAID funded a Wuhan Institute of Virology project on bat coronavirus, and the U.S. Department of Energy now confirms that Coronavirus likely emerged from the Wuhan lab. Patrick Howley’s Fauci-Wuhan reporting for NATIONAL FILE was featured in the trailer for the Robert F. Kennedy Junior truther documentary The Real Anthony Fauci: The Movie.

NATIONAL FILE also reported that the University of Pennsylvania, which hosts and funds Joe Biden’s think tank the Penn Biden Center, makes money from the Pfizer-BioNTech vaccine and the Moderna vaccine, and actually receives milestone payments for more vaccines sold.

In June 2020, NATIONAL FILE reported: “National Institutes of Health (NIH) own a financial stake in the Bill Gates-funded Moderna Coronavirus vaccine, raising big questions about the supposed impartiality of the federal government’s policy decisions during the Coronavirus outbreak. NIAID director Dr. Anthony Fauci, a financial ally of Bill Gates whose institute is part of NIH, has been critical of Hydroxychloroquine and the FBI even raided a health spa serving intravenous vitamin C, which are competitors to a vaccine. (RELATED: Eight NIH Coronavirus Panel Experts Disclose Financial Relationships With Price-Hiking Drugmaker Gilead).

“We do have some particular stake in the intellectual property” for the Moderna vaccine stated Francis Collins, the director of NIH, in a revelatory recent Economic Club panel discussion. “One of the vaccines– the one that’s furthest along– what started, actually, at the federal government in our own Vaccine Research Center at NIH– then worked with a biotechnology company called Moderna to get to where we are now, with very impressive Phase I results and getting ready to go into a large-scale trial as early as July. That one, of course, we do have some particular stake in the intellectual property. Others, though, come from companies who’ve invested their efforts into getting them to the point where they might now be ready for a trial,” Collins stated.”